Trial Profile
Safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2015
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension; Raynaud's disease
- Focus Pharmacokinetics
- 10 Nov 2015 New trial record